Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H13N5O4 |
Molecular Weight | 279.252 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C2=CC=C(C3=NO[N+]([O-])=C23)[N+]([O-])=O
InChI
InChIKey=MWFZDJLPWDCQIL-UHFFFAOYSA-N
InChI=1S/C11H13N5O4/c1-13-4-6-14(7-5-13)9-3-2-8(15(17)18)10-11(9)16(19)20-12-10/h2-3H,4-7H2,1H3
Molecular Formula | C11H13N5O4 |
Molecular Weight | 279.252 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21075910Curator's Comment: description was created based on several sources, including
http://google.com/patents/WO2011014825A3 | https://www.google.com/patents/WO2015054374A3 | https://www.ncbi.nlm.nih.gov/pubmed/26095524 | https://www.ncbi.nlm.nih.gov/pubmed/26311300
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21075910
Curator's Comment: description was created based on several sources, including
http://google.com/patents/WO2011014825A3 | https://www.google.com/patents/WO2015054374A3 | https://www.ncbi.nlm.nih.gov/pubmed/26095524 | https://www.ncbi.nlm.nih.gov/pubmed/26311300
NSC-207895 (XI-006) is a derivative of nitrobenzofuroxan and an anticancer agent with an EC50 of 1 μM. NSC-207895 also upregulated the expression of p53 in MCF-7 cells that led to increased expression of proapoptotic genes including PUMA, BAX, as well as PIG3. Notably, NSC-207895, also called a small-molecule p53 activator, gives rise to MCF-7 cells to experience apoptosis and decrease the viability of cancer cells along with nutlin-3a, which dissociated the MDM2-p53 complex. NSC-207895 is an electrophilic compound that has antitumor and mutagenic activities. NSC-207895 may lead to the damage of DNA that inhibits the growth of tumors.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4096 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21075910 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://google.com/patents/WO2011014825A3 |
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26095524
MCF-7 cells were treated with 0.5 mg/mL of DOX or XI-006 (NSC-207895, 1, 2, 5 mkM) for 16 hours and lysed to measure p53 phosphorylation levels.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:02:48 GMT 2023
by
admin
on
Fri Dec 15 18:02:48 GMT 2023
|
Record UNII |
63J576F4C5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
207895
Created by
admin on Fri Dec 15 18:02:48 GMT 2023 , Edited by admin on Fri Dec 15 18:02:48 GMT 2023
|
PRIMARY | |||
|
63J576F4C5
Created by
admin on Fri Dec 15 18:02:48 GMT 2023 , Edited by admin on Fri Dec 15 18:02:48 GMT 2023
|
PRIMARY | |||
|
179940
Created by
admin on Fri Dec 15 18:02:48 GMT 2023 , Edited by admin on Fri Dec 15 18:02:48 GMT 2023
|
PRIMARY | |||
|
58131-57-0
Created by
admin on Fri Dec 15 18:02:48 GMT 2023 , Edited by admin on Fri Dec 15 18:02:48 GMT 2023
|
PRIMARY | |||
|
DTXSID50206858
Created by
admin on Fri Dec 15 18:02:48 GMT 2023 , Edited by admin on Fri Dec 15 18:02:48 GMT 2023
|
PRIMARY | |||
|
42640
Created by
admin on Fri Dec 15 18:02:48 GMT 2023 , Edited by admin on Fri Dec 15 18:02:48 GMT 2023
|
PRIMARY |